Prenatal Exposure to Selective Serotonin Reuptake Inhibitors and Infant Outcome

@article{Malm2012PrenatalET,
  title={Prenatal Exposure to Selective Serotonin Reuptake Inhibitors and Infant Outcome},
  author={H. Malm},
  journal={Therapeutic Drug Monitoring},
  year={2012},
  volume={34},
  pages={607–614}
}
  • H. Malm
  • Published 2012
  • Medicine
  • Therapeutic Drug Monitoring
Background: The selective serotonin reuptake inhibitors are prescribed increasingly also during pregnancy. Although a number of studies have assessed their safety, data concerning congenital malformations and adverse perinatal outcome are conflicting. Methods: Literature search in PubMed until March 31, 2012, including original research articles, meta-analyses, and reviews. Results: Fluoxetine and paroxetine use in early pregnancy has been associated with a small increased risk for specific… Expand
Use of Selective Serotonin Reuptake Inhibitors During Pregnancy and Risk of Congenital Cardiac Malformations
TLDR
The studies demonstrated low risk of congenital cardiac malformation with exposure to SSRIs as a general class, however, paroxetine and sertraline exposure showed elevated risk that was sometimes considered significant. Expand
Maternal use of selective serotonin reuptake inhibitors during pregnancy is associated with Hirschsprung’s disease in newborns – a nationwide cohort study
TLDR
Early maternal use of selective serotonin reuptake inhibitors is significantly associated with the development of Hirschsprung’s disease in the newborn child, and treatment of depression during pregnancy always has to be weighed against the risks posed by untreated maternal depression. Expand
Long-Term Outcomes of Developmental Exposure to Fluoxetine: A Review of the Animal Literature
TLDR
It is clear that early FLX exposure in non-human animals can alter the development of the brain in ways that are relevant to behaviour in adulthood, decreasing exploration and social interaction, and in some cases altering anxiety- and depression-like behaviours. Expand
Autism spectrum disorder and prenatal exposure to selective serotonin reuptake inhibitors: A systematic review and meta-analysis.
TLDR
It is concluded that SSRI use in pregnancy is associated with an increased risk of ASD in the offspring, but maternal psychiatric condition is a major confounding factor. Expand
Antidepressant use during pregnancy and the risk of major congenital malformations in a cohort of depressed pregnant women: an updated analysis of the Quebec Pregnancy Cohort
TLDR
Antidepressants with effects on serotonin reuptake during embryogenesis increased the risk of some organ-specific malformations in a cohort of pregnant women with depression. Expand
What are the risks associated with different Selective Serotonin Re-uptake Inhibitors (SSRIs) to treat depression and anxiety in pregnancy? An evaluation of current evidence.
TLDR
Sertraline and citalopram should be first-line drug treatments for anxiety and depression in pregnant women in the SSRI class. Expand
Pregnancy Outcome Following Maternal Exposure to Mirtazapine: A Multicenter, Prospective Study
TLDR
Pregnancy outcomes after exposure to mirtazapine were compared with 2 matched control groups: exposure to any selective serotonin reuptake inhibitor (SSRI, control subjects with a psychiatric condition) and no exposure to medication known to be teratogenic or any antidepressant (general control subjects). Expand
Risk for Autism Spectrum Disorders According to Period of Prenatal Antidepressant Exposure: A Systematic Review and Meta-analysis
TLDR
There is a significant association between increased ASD risk and maternal use of antidepressants during pregnancy; however, it appears to be more consistent during the preconception period than during each trimester. Expand
The use of psychotropic medication during pregnancy: how about the newborn?
TLDR
Infants are at risk of developing symptoms of Poor Neonatal Adaptation after exposure to psychotropic drugs in utero, breastfeeding is presumably protective for development of PNA, and Phenobarbital is a safe therapeutic option. Expand
Prenatal Exposure to Acetaminophen and Risk for Attention Deficit Hyperactivity Disorder and Autistic Spectrum Disorder: A Systematic Review, Meta-Analysis, and Meta-Regression Analysis of Cohort Studies
TLDR
Findings are concerning; however, results should be interpreted with caution given that the available evidence consists of observational studies and is susceptible to several potential sources of bias. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 97 REFERENCES
Risks associated with in utero and lactation exposure to selective serotonin reuptake inhibitors (SSRIs).
TLDR
There is no conclusive evidence for increased risk for malformations but paroxetine and possibly fluoxetines use in early pregnancy may be associated with a small increased risk with regard to cardiovascularmalformations. Expand
Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations.
TLDR
Use of SSRIs in early pregnancy does not seem to be a major risk factor for infant malformations, and the association between paroxetine use and infant cardiovascular defects may be a result of multiple testing, but is supported by other studies. Expand
Selective serotonin reuptake inhibitors and risk for major congenital anomalies.
TLDR
The authors’ conclusions that selective serotonin reuptake inhibitors taken during pregnancy increase the risks for congenital defects in the offspring of mothers who took SSRIs compared with unexposed referent offspring are disturbing and should be published with rigorous methodologies and detailed discussion of the limitations. Expand
Risks Associated With Selective Serotonin Reuptake Inhibitors in Pregnancy
TLDR
Use of SSRIs during pregnancy is not independently associated with increased risk of adverse perinatal outcome other than need for treatment in neonatal special or intensive care unit. Expand
Maternal Use of Selective Serotonin Reuptake Inhibitors and Risk of Congenital Malformations
TLDR
An increased risk of congenital malformations after exposure to SSRIs in early pregnancy is found, although it is unclear whether the effects were causal or due to factors related to the underlying disease. Expand
Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study.
TLDR
The new SSRIs, fluvoxamine, paroxetine, and sertraline, do not appear to increase the teratogenic risk when used in their recommended doses. Expand
Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects.
TLDR
Maternal use of SSRIs during early pregnancy was not associated with significantly increased risks of congenital heart defects or of most other categories of birth defects. Expand
Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn.
TLDR
Data support an association between the maternal use of SSRIs in late pregnancy and PPHN in the offspring; these findings should be taken into account in decisions as to whether to continue the use ofSSRIs during pregnancy. Expand
Major congenital malformations following prenatal exposure to serotonin reuptake inhibitors and benzodiazepines using population-based health data.
TLDR
Infants exposed to prenatal SRIs in combination with BZs had a higher a incidence of CHD compared to no exposure, even after controlling for maternal illness characteristics, and SRI monotherapy was not associated with an increased risk for major CA, but was associated with a increased incidence of ASD. Expand
Selective serotonin reuptake inhibitor exposure in utero and pregnancy outcomes.
TLDR
Exposure to SSRIs during pregnancy was associated with an increased risk of preterm delivery, a low 5-minute Apgar score, and neonatal intensive care unit admission, which was not explained by lower Apgar scores or gestational age. Expand
...
1
2
3
4
5
...